1. Williams NR, McRae K, Houghton J: Delays in ethics committee approval: an English perspective [abstract]. Breast Cancer Res Treat. 2003, 82 (suppl 1): S80-
2. The European Parliament and the Council of the European Union: Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Communities. 2001, L121: 34-44.
3. Baum M, Buchanan M, Baselga J, Cataliotti L, Jassem J, Piccart M: The future of breast cancer research in danger. Eur J Cancer. 2002, 38: 2210-2213. 10.1016/S0959-8049(02)00482-3.
4. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139. 10.1016/S0140-6736(02)09088-8.
5. Baum M: Background. In History and Advancement of Anastrozole in the Treatment of Breast Cancer. Edited by: Buzdar A, Baum M. 2003, London: The Royal Society of Medicine Press, 3-6.